Kyverna Therapeutics Inc KYTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KYTX is a good fit for your portfolio.
News
-
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
-
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
-
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
-
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
-
Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Wall Street hungry for IPO of Mexican supermarket chain BBB Foods as stock rises 9%
-
Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering
Trading Information
- Previous Close Price
- $15.47
- Day Range
- $13.96–15.80
- 52-Week Range
- $13.96–35.06
- Bid/Ask
- $13.96 / $18.65
- Market Cap
- $647.16 Mil
- Volume/Avg
- 995,709 / 493,781
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 84
- Website
- https://www.kyvernatx.com
Valuation
|
Metric
|
KYTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KYTX
|
|---|---|
Quick Ratio | 2.90 |
Current Ratio | 3.05 |
Interest Coverage | −334.02 |
Quick Ratio
KYTX
Profitability
|
Metric
|
KYTX
|
|---|---|
Return on Assets (Normalized) | −74.35% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
KYTX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mbdfkqztp | Wxjj | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mcpwlfcyn | Hxwyrfj | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pnnsxdsc | Nbfcxrj | $97.8 Bil | |
MRNA
| Moderna Inc | Nntcrzgt | Ylxm | $41.3 Bil | |
ARGX
| argenx SE ADR | Vtbqpgs | Nzgp | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Mmfxffxl | Wpqb | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ggftfkq | Vlbbyz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Csvyzsvh | Pzrwtr | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xmrrkyvgkx | Yvjkd | $12.5 Bil | |
INCY
| Incyte Corp | Myyfmyt | Xxfwdq | $11.6 Bil |